Reason for request
New indication
Clinical Benefit
| Insufficient |
The Committee deems that the clinical benefit of LIBTAYO (cemiplimab) in association with a platinum salt-based chemotherapy regimen, is insufficient in the MA indication to justify public funding. |
Clinical Added Value
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
bmTUNf4q53q8dcnB
